Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,724 recalls · Class II, newest first

Class II · Moderate risk

Inflectra (infliximab-dyyb)

cGMP Deviations: Product intended for quarantine was inadvertently distributed.

Ongoing cGMP deviation McKesson NDC 0069-0809-01 D-0213-2025
Class II · Moderate risk

Henry Schein

CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Terminated cGMP deviation Keystone Industries D-0148-2025
Class II · Moderate risk

Ipana

CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Terminated cGMP deviation Keystone Industries D-0147-2025

Recalls by year